ACB vs. AVXL, ABCL, AVBP, COGT, PAHC, RLAY, CDMO, SANA, SEPN, and TYRA
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Relay Therapeutics (RLAY), Avid Bioservices (CDMO), Sana Biotechnology (SANA), Septerna (SEPN), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.
Aurora Cannabis vs.
Anavex Life Sciences (NASDAQ:AVXL) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.
Anavex Life Sciences received 51 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 74.57% of users gave Anavex Life Sciences an outperform vote while only 59.56% of users gave Aurora Cannabis an outperform vote.
In the previous week, Anavex Life Sciences had 10 more articles in the media than Aurora Cannabis. MarketBeat recorded 12 mentions for Anavex Life Sciences and 2 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.35 beat Anavex Life Sciences' score of 0.25 indicating that Aurora Cannabis is being referred to more favorably in the news media.
Anavex Life Sciences presently has a consensus price target of $44.00, indicating a potential upside of 377.74%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Aurora Cannabis.
Anavex Life Sciences has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.
Anavex Life Sciences has higher earnings, but lower revenue than Aurora Cannabis. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Anavex Life Sciences has a net margin of 0.00% compared to Aurora Cannabis' net margin of -17.47%. Aurora Cannabis' return on equity of -2.19% beat Anavex Life Sciences' return on equity.
Summary
Anavex Life Sciences beats Aurora Cannabis on 8 of the 15 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
This page (NASDAQ:ACB) was last updated on 1/21/2025 by MarketBeat.com Staff
